Skip to main content
Top
Published in: International Journal of Clinical Oncology 1/2012

01-02-2012 | Review Article

Pathological and molecular biological approaches to early mesothelioma

Authors: Tohru Tsujimura, Ikuko Torii, Ayuko Sato, Misa Song, Kazuya Fukuoka, Seiki Hasegawa, Takashi Nakano

Published in: International Journal of Clinical Oncology | Issue 1/2012

Login to get access

Abstract

Malignant mesothelioma is an asbestos-related malignancy that arises primarily from mesothelial cells on the serosal surfaces of the pleural, peritoneal, and pericardial cavities. Malignant pleural mesothelioma (MPM) is most common, and its incidence is dramatically increasing worldwide as a result of widespread use of asbestos. Morphological discrimination between MPM and reactive mesothelial hyperplasia is difficult, and the most reliable pathological criterion for malignancy is mesothelial proliferation invading deeply into subpleural adipose tissues. To establish radical cure of MPM, it is crucial to find early-stage MPM of epithelial type, in which mesothelial proliferation is localized on the serosal surface of parietal pleura or limited within the submesothelial fibrous tissues of parietal pleura. The initial clinical presentation for patients with MPM is frequently dyspnea and/or chest pain due to large pleural effusion, and cytological analysis of pleural effusions is valuable to find patients with early-stage MPM of epithelial type. Recently, cytological features of MPM in pleural effusion, molecular markers for MPM, and genetic alternations of MPM have been reported. In this review, we discuss major issues on pathological and molecular biological approaches for diagnosis of early-stage MPM of epithelial type.
Literature
1.
go back to reference Robinson BWS, Chahinian AP (2002) Mesothelioma. Martin Dunitz Ltd, London Robinson BWS, Chahinian AP (2002) Mesothelioma. Martin Dunitz Ltd, London
2.
3.
4.
go back to reference Tsao AS, Wistuba I, Roth JA et al (2009) Malignant pleural mesothelioma. J Clin Oncol 27:2081–2090CrossRefPubMed Tsao AS, Wistuba I, Roth JA et al (2009) Malignant pleural mesothelioma. J Clin Oncol 27:2081–2090CrossRefPubMed
6.
go back to reference Travis WD, Brambilla E, Muller-Hermelink HK et al (2004) World Health Organization classification of tumours, pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon Travis WD, Brambilla E, Muller-Hermelink HK et al (2004) World Health Organization classification of tumours, pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon
7.
go back to reference Sugarbaker DJ, Mentzer SJ, Strauss G (1992) Extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma. Ann Thorac Surg 54:941–946CrossRefPubMed Sugarbaker DJ, Mentzer SJ, Strauss G (1992) Extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma. Ann Thorac Surg 54:941–946CrossRefPubMed
8.
go back to reference Churg A, Colby TV, Cagle P et al (2000) The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 24:1183–1200CrossRefPubMed Churg A, Colby TV, Cagle P et al (2000) The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 24:1183–1200CrossRefPubMed
9.
go back to reference Churg A, Cagle PT, Roggli VL (2006) Separation of benign and malignant mesothelial proliferations. In: Silverberg SG, Sobin LH (eds) AFIP Atlas of tumor pathology: tumors of the serosal membranes. 4th series, fascicle 3. American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology, Washington, pp 83–101 Churg A, Cagle PT, Roggli VL (2006) Separation of benign and malignant mesothelial proliferations. In: Silverberg SG, Sobin LH (eds) AFIP Atlas of tumor pathology: tumors of the serosal membranes. 4th series, fascicle 3. American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology, Washington, pp 83–101
10.
go back to reference Stevens MW, Leong AS, Fazzalari NL et al (1992) Cytopathology of malignant mesothelioma: a stepwise logistic regression analysis. Diagn Cytopathol 8:333–341CrossRefPubMed Stevens MW, Leong AS, Fazzalari NL et al (1992) Cytopathology of malignant mesothelioma: a stepwise logistic regression analysis. Diagn Cytopathol 8:333–341CrossRefPubMed
12.
go back to reference Churg A, Cagle PT, Roggli VL (2006) Cytology of the serosal surfaces. In: Silverberg SG, Sobin LH (eds) AFIP Atlas of tumor pathology: tumors of the serosal membranes. 4th series, fascicle 3. American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology, Washington, pp 11–31 Churg A, Cagle PT, Roggli VL (2006) Cytology of the serosal surfaces. In: Silverberg SG, Sobin LH (eds) AFIP Atlas of tumor pathology: tumors of the serosal membranes. 4th series, fascicle 3. American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology, Washington, pp 11–31
13.
go back to reference Cakir E, Demirag F, Aydin M et al (2009) Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: a logistic regression analysis. Diagn Cytopathol 37:4–10CrossRefPubMed Cakir E, Demirag F, Aydin M et al (2009) Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: a logistic regression analysis. Diagn Cytopathol 37:4–10CrossRefPubMed
14.
go back to reference Kimura N, Data K, Araya Y et al (2009) Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens. Diagn Cytopathol 37:885–890CrossRefPubMed Kimura N, Data K, Araya Y et al (2009) Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens. Diagn Cytopathol 37:885–890CrossRefPubMed
15.
go back to reference Kato Y, Tsuta K, Seki K et al (2007) Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 20:215–220CrossRefPubMed Kato Y, Tsuta K, Seki K et al (2007) Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 20:215–220CrossRefPubMed
16.
go back to reference Sato A, Torii I, Okamura Y et al (2010) Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol 23:1458–1466CrossRefPubMed Sato A, Torii I, Okamura Y et al (2010) Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol 23:1458–1466CrossRefPubMed
17.
go back to reference Shen J, Pinkus GS, Deshpande V et al (2009) Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol 131:516–523CrossRefPubMed Shen J, Pinkus GS, Deshpande V et al (2009) Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol 131:516–523CrossRefPubMed
18.
go back to reference Shi M, Fraire AE, Chu P et al (2011) Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol 35:878–882CrossRefPubMed Shi M, Fraire AE, Chu P et al (2011) Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol 35:878–882CrossRefPubMed
19.
go back to reference van der Bij S, Schaake E, Koffijberg H et al (2011) Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer 104:1325–1333CrossRefPubMed van der Bij S, Schaake E, Koffijberg H et al (2011) Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer 104:1325–1333CrossRefPubMed
20.
go back to reference Cagle PT, Churg A (2005) Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med 129:1421–1427PubMed Cagle PT, Churg A (2005) Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med 129:1421–1427PubMed
21.
go back to reference Husain AN, Colby TV, Ordonez NG et al (2009) Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 133:1317–1331PubMed Husain AN, Colby TV, Ordonez NG et al (2009) Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 133:1317–1331PubMed
22.
go back to reference Klebe S, Henderson DW (2011) Early stages of mesothelioma, screening and biomarkers. Recent Results Cancer Res 189:169–193CrossRefPubMed Klebe S, Henderson DW (2011) Early stages of mesothelioma, screening and biomarkers. Recent Results Cancer Res 189:169–193CrossRefPubMed
23.
go back to reference Whitaker D, Henderson DW, Shilkin KB (1992) The concept of mesothelioma in situ: implications for diagnosis and histogenesis. Semin Diagn Pathol 9:151–161PubMed Whitaker D, Henderson DW, Shilkin KB (1992) The concept of mesothelioma in situ: implications for diagnosis and histogenesis. Semin Diagn Pathol 9:151–161PubMed
24.
go back to reference Henderson DW, Shilkin KB, Whitaker D (1998) Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Pathol 110:397–404PubMed Henderson DW, Shilkin KB, Whitaker D (1998) Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Pathol 110:397–404PubMed
25.
go back to reference Hammar SP, Henderson DW, Klebe S et al (2008) Neoplasms of the pleura. In: Tomashefski JFJ (ed) Dail and Hammar’s pulmonary pathology, chap 43, vol 2, 3rd edn. Springer, New York, pp 558–734CrossRef Hammar SP, Henderson DW, Klebe S et al (2008) Neoplasms of the pleura. In: Tomashefski JFJ (ed) Dail and Hammar’s pulmonary pathology, chap 43, vol 2, 3rd edn. Springer, New York, pp 558–734CrossRef
26.
go back to reference Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108:1122–1128CrossRefPubMed Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108:1122–1128CrossRefPubMed
27.
go back to reference Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710–1717CrossRefPubMed Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710–1717CrossRefPubMed
28.
go back to reference Kamei T (2010) Cytological diagnosis for mesothelioma. In: An abstract of the 10th international conference of the international mesothelioma interest group, Aug 31–Sept 3, 2010 Kyoto, Japan, p 36 Kamei T (2010) Cytological diagnosis for mesothelioma. In: An abstract of the 10th international conference of the international mesothelioma interest group, Aug 31–Sept 3, 2010 Kyoto, Japan, p 36
29.
go back to reference Churg A, Cagle PT, Roggli VL (2006) Diffuse malignant tumors of the serosal membranes. In: Silverberg SG, Sobin LH (eds) AFIP Atlas of tumor pathology: tumors of the serosal membranes. 4th series, fascicle 3. American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology, Washington, pp 33–82 Churg A, Cagle PT, Roggli VL (2006) Diffuse malignant tumors of the serosal membranes. In: Silverberg SG, Sobin LH (eds) AFIP Atlas of tumor pathology: tumors of the serosal membranes. 4th series, fascicle 3. American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology, Washington, pp 33–82
30.
go back to reference Fetsch PA, Abati A (2001) Immunocytochemistry in effusion cytology: a contemporary review. Cancer 93:293–308CrossRefPubMed Fetsch PA, Abati A (2001) Immunocytochemistry in effusion cytology: a contemporary review. Cancer 93:293–308CrossRefPubMed
31.
go back to reference Pu RT, Pang Y, Michael CW (2008) Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. Diagn Cytopathol 36:20–25CrossRefPubMed Pu RT, Pang Y, Michael CW (2008) Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. Diagn Cytopathol 36:20–25CrossRefPubMed
32.
go back to reference Bishop JA, Sharma R, Illei PB (2010) Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, and malignant mesothelioma. Hum Pathol 41:20–25CrossRefPubMed Bishop JA, Sharma R, Illei PB (2010) Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, and malignant mesothelioma. Hum Pathol 41:20–25CrossRefPubMed
33.
go back to reference Khoor A, Whitsett JA, Stahlman MT et al (1999) Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol 30:695–700CrossRefPubMed Khoor A, Whitsett JA, Stahlman MT et al (1999) Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol 30:695–700CrossRefPubMed
34.
go back to reference Wolanski KD, Whitaker D, Shilkin KB et al (1998) The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses. Cancer 82:583–590CrossRefPubMed Wolanski KD, Whitaker D, Shilkin KB et al (1998) The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses. Cancer 82:583–590CrossRefPubMed
35.
go back to reference Saad RS, Cho P, Liu YL (2005) The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol 32:156–159CrossRefPubMed Saad RS, Cho P, Liu YL (2005) The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol 32:156–159CrossRefPubMed
36.
go back to reference Attanoos RL, Griffin A, Gibbs AR (2003) The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 43:231–238CrossRefPubMed Attanoos RL, Griffin A, Gibbs AR (2003) The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 43:231–238CrossRefPubMed
37.
go back to reference Ramael M, Lemmens G, Eerdekens C et al (1992) Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol 168:371–375CrossRefPubMed Ramael M, Lemmens G, Eerdekens C et al (1992) Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol 168:371–375CrossRefPubMed
38.
go back to reference Hurlimann J (1994) Desmin and neural marker expression in mesothelial cells and mesotheliomas. Hum Pathol 25:753–757CrossRefPubMed Hurlimann J (1994) Desmin and neural marker expression in mesothelial cells and mesotheliomas. Hum Pathol 25:753–757CrossRefPubMed
39.
go back to reference Davidson B, Nielsen S, Christensen J et al (2001) The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 25:1405–1412CrossRefPubMed Davidson B, Nielsen S, Christensen J et al (2001) The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 25:1405–1412CrossRefPubMed
40.
go back to reference Cury PM, Butcher DN, Corrin B et al (1999) The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol 189:251–257CrossRefPubMed Cury PM, Butcher DN, Corrin B et al (1999) The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol 189:251–257CrossRefPubMed
41.
go back to reference King J, Thatcher N, Pickering C et al (2006) Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology 49:561–568CrossRefPubMed King J, Thatcher N, Pickering C et al (2006) Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology 49:561–568CrossRefPubMed
42.
go back to reference Kumaki F, Kawai T, Churg A et al (2002) Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas. Am J Surg Pathol 26:365–370CrossRefPubMed Kumaki F, Kawai T, Churg A et al (2002) Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas. Am J Surg Pathol 26:365–370CrossRefPubMed
43.
go back to reference Xio S, Li D, Vijg J et al (1995) Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 11:511–515PubMed Xio S, Li D, Vijg J et al (1995) Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 11:511–515PubMed
44.
go back to reference Prins JB, Williamson KA, Kamp MM et al (1998) The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 75:649–653CrossRefPubMed Prins JB, Williamson KA, Kamp MM et al (1998) The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 75:649–653CrossRefPubMed
45.
go back to reference Onofre FB, Onofre AS, Pomjanski N et al (2008) 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis. Cancer 114:204–215CrossRefPubMed Onofre FB, Onofre AS, Pomjanski N et al (2008) 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis. Cancer 114:204–215CrossRefPubMed
46.
go back to reference Takeda M, Kasai T, Enomoto Y et al (2010) 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int 60:395–399CrossRefPubMed Takeda M, Kasai T, Enomoto Y et al (2010) 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int 60:395–399CrossRefPubMed
47.
go back to reference Chung CT, Santos Gda C, Hwang DM et al (2010) FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol 63:630–634CrossRefPubMed Chung CT, Santos Gda C, Hwang DM et al (2010) FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol 63:630–634CrossRefPubMed
48.
go back to reference Monaco SE, Shuai Y, Bansal M et al (2011) The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol 135:619–627CrossRefPubMed Monaco SE, Shuai Y, Bansal M et al (2011) The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol 135:619–627CrossRefPubMed
49.
go back to reference Altomare DA, Menges CW, Xu J et al (2011) Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PloS One 6:e18828CrossRefPubMed Altomare DA, Menges CW, Xu J et al (2011) Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PloS One 6:e18828CrossRefPubMed
50.
go back to reference Sekido Y, Pass HI, Bader S et al (1995) Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 55:1227–1231PubMed Sekido Y, Pass HI, Bader S et al (1995) Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 55:1227–1231PubMed
51.
go back to reference Bianchi AB, Mitsunaga SI, Cheng JQ et al (1995) High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 92:10854–10858CrossRefPubMed Bianchi AB, Mitsunaga SI, Cheng JQ et al (1995) High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 92:10854–10858CrossRefPubMed
52.
go back to reference Baser ME (2006) The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene. Hum Mutat 27:297–306CrossRefPubMed Baser ME (2006) The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene. Hum Mutat 27:297–306CrossRefPubMed
53.
go back to reference McClatchey AI, Giovannini M (2005) Membrane organization and tumorigenesis—the NF2 tumor suppressor, Merlin. Genes Dev 19:2265–2277CrossRefPubMed McClatchey AI, Giovannini M (2005) Membrane organization and tumorigenesis—the NF2 tumor suppressor, Merlin. Genes Dev 19:2265–2277CrossRefPubMed
54.
go back to reference Murakami H, Mizuno T, Taniguchi T et al (2011) LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res 71:873–883CrossRefPubMed Murakami H, Mizuno T, Taniguchi T et al (2011) LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res 71:873–883CrossRefPubMed
55.
go back to reference Altomare DA, Vaslet CA, Skele KL et al (2005) A mouse model recapitulating molecular features of human mesothelioma. Cancer Res 65:8090–8095CrossRefPubMed Altomare DA, Vaslet CA, Skele KL et al (2005) A mouse model recapitulating molecular features of human mesothelioma. Cancer Res 65:8090–8095CrossRefPubMed
56.
go back to reference Jensen DE, Proctor M, Marquis ST et al (1998) BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16:1097–1112CrossRefPubMed Jensen DE, Proctor M, Marquis ST et al (1998) BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16:1097–1112CrossRefPubMed
57.
go back to reference Nishikawa H, Wu W, Koike A et al (2009) BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res 69:111–119CrossRefPubMed Nishikawa H, Wu W, Koike A et al (2009) BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res 69:111–119CrossRefPubMed
58.
go back to reference Harbour JW, Onken MD, Roberson ED et al (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330:1410–1413CrossRefPubMed Harbour JW, Onken MD, Roberson ED et al (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330:1410–1413CrossRefPubMed
59.
go back to reference Bott M, Brevet M, Taylor BS et al (2011) The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 43:668–672CrossRefPubMed Bott M, Brevet M, Taylor BS et al (2011) The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 43:668–672CrossRefPubMed
60.
go back to reference Testa JR, Cheung M, Pei J et al (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43:1022–1025CrossRefPubMed Testa JR, Cheung M, Pei J et al (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43:1022–1025CrossRefPubMed
61.
go back to reference Yoshikawa Y, Sato A, Tsujimura T et al (2011) Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells. Int J Oncol 39:1365–1374PubMed Yoshikawa Y, Sato A, Tsujimura T et al (2011) Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells. Int J Oncol 39:1365–1374PubMed
62.
go back to reference Taniguchi T, Karnan S, Fukui T et al (2007) Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci 98:438–446CrossRefPubMed Taniguchi T, Karnan S, Fukui T et al (2007) Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci 98:438–446CrossRefPubMed
63.
go back to reference Destro A, Ceresoli GL, Falleni M et al (2006) EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 51:207–215CrossRefPubMed Destro A, Ceresoli GL, Falleni M et al (2006) EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 51:207–215CrossRefPubMed
64.
go back to reference Altomare DA, You H, Xiao GH et al (2005) Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24:6080–6089CrossRefPubMed Altomare DA, You H, Xiao GH et al (2005) Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24:6080–6089CrossRefPubMed
65.
go back to reference Suzuki Y, Murakami H, Kawaguchi K et al (2009) Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Rep 2:181–188 Suzuki Y, Murakami H, Kawaguchi K et al (2009) Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Rep 2:181–188
66.
go back to reference Papp T, Schipper H, Pemsel H et al (2001) Mutational analysis of the PTEN/MMAC1 tumour suppressor gene in primary human malignant mesotheliomas. Oncol Rep 8:1375–1379PubMed Papp T, Schipper H, Pemsel H et al (2001) Mutational analysis of the PTEN/MMAC1 tumour suppressor gene in primary human malignant mesotheliomas. Oncol Rep 8:1375–1379PubMed
67.
go back to reference Kratzke RA, Otterson GA, Lincoln CE et al (1995) Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 87:1870–1875CrossRefPubMed Kratzke RA, Otterson GA, Lincoln CE et al (1995) Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 87:1870–1875CrossRefPubMed
68.
go back to reference Papp T, Schipper H, Pemsel H et al (2001) Mutational analysis of N-ras, p53, p16 INK4a , p14 ARF and CDK4 genes in primary human malignant mesotheliomas. Int J Oncol 18:425–433PubMed Papp T, Schipper H, Pemsel H et al (2001) Mutational analysis of N-ras, p53, p16 INK4a , p14 ARF and CDK4 genes in primary human malignant mesotheliomas. Int J Oncol 18:425–433PubMed
69.
go back to reference Thomas RK, Baker AC, Debiasi RM et al (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:347–351CrossRefPubMed Thomas RK, Baker AC, Debiasi RM et al (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:347–351CrossRefPubMed
Metadata
Title
Pathological and molecular biological approaches to early mesothelioma
Authors
Tohru Tsujimura
Ikuko Torii
Ayuko Sato
Misa Song
Kazuya Fukuoka
Seiki Hasegawa
Takashi Nakano
Publication date
01-02-2012
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 1/2012
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-011-0369-1

Other articles of this Issue 1/2012

International Journal of Clinical Oncology 1/2012 Go to the issue

Introduction to Review Articles

Early mesothelioma revisited

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine